"Dinoprostone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
| Descriptor ID |
D015232
|
| MeSH Number(s) |
D10.251.355.255.550.250.200 D23.469.050.175.725.250.200
|
| Concept/Terms |
Dinoprostone- Dinoprostone
- PGE2 alpha
- alpha, PGE2
- Prostaglandin E2alpha
- E2alpha, Prostaglandin
- Prostaglandin E2
- E2, Prostaglandin
- Prostaglandin E2 alpha
- E2 alpha, Prostaglandin
- alpha, Prostaglandin E2
- PGE2
- PGE2alpha
|
Below are MeSH descriptors whose meaning is more general than "Dinoprostone".
Below are MeSH descriptors whose meaning is more specific than "Dinoprostone".
This graph shows the total number of publications written about "Dinoprostone" by people in this website by year, and whether "Dinoprostone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 4 | 4 |
| 2003 | 1 | 2 | 3 |
| 2004 | 0 | 3 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 1 | 5 |
| 2008 | 3 | 3 | 6 |
| 2009 | 4 | 1 | 5 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 1 | 1 |
| 2022 | 2 | 3 | 5 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dinoprostone" by people in Profiles.
-
Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer. Gut. 2025 Mar 06; 74(4):586-602.
-
Latest advancements in the study of the relationship between NSAIDs and three prostaglandin E2 synthases. Future Med Chem. 2023 09; 15(17):1549-1552.
-
Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun. 2023 07; 3(7):1397-1408.
-
Design, synthesis and characterization of lead compounds as anti-inflammatory drugs targeting mPGES-1 via enzymelink screening. Future Med Chem. 2023 05; 15(9):757-767.
-
Stabilization of E-cadherin adhesions by COX-2/GSK3? signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023 03 22; 8(6).
-
Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer. 2022 08; 10(8).
-
Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity. Pancreas. 2022 08 01; 51(7):723-732.
-
Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Rep. 2022 06 21; 39(12):111000.
-
Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke. Neurotherapeutics. 2022 01; 19(1):366-385.
-
Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E2 synthase-1. Future Med Chem. 2022 03; 14(6):385-388.